• Something wrong with this record ?

Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence

S. Renzi, O. Michaeli, H. Salvador, D. Alderete, NF. Ponce, M. Zapotocky, JR. Hansford, VS. Malalasekera, H. Toledano, B. Maguire, E. Bouffet, V. Ramaswamy, LV. Baroni,

. 2020 ; 67 (5) : e28228. [pub] 20200302

Language English Country United States

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20025064

Grant support
CIHR - Canada

Seventeen children at six institutions with neurofibromatosis type 2 (NF2)-related vestibular schwannomas received bevacizumab. Eight of the 13 patients with initial hearing loss (61%) showed objective hearing improvement within six months of treatment. No patients showed hearing deterioration during therapy; however, only two patients showed objective radiological response. Seven of eight patients had tumor progression or worsening hearing loss upon cessation of treatment. Bevacizumab was well tolerated with no patients discontinuing therapy. Bevacizumab appears to postpone hearing loss in childhood NF2-associated vestibular schwannomas, but responses are not durable, suggesting that either longer maintenance therapy or new strategies are required.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025064
003      
CZ-PrNML
005      
20201222155032.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pbc.28228 $2 doi
035    __
$a (PubMed)32124552
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Renzi, Samuele $u Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
245    10
$a Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence / $c S. Renzi, O. Michaeli, H. Salvador, D. Alderete, NF. Ponce, M. Zapotocky, JR. Hansford, VS. Malalasekera, H. Toledano, B. Maguire, E. Bouffet, V. Ramaswamy, LV. Baroni,
520    9_
$a Seventeen children at six institutions with neurofibromatosis type 2 (NF2)-related vestibular schwannomas received bevacizumab. Eight of the 13 patients with initial hearing loss (61%) showed objective hearing improvement within six months of treatment. No patients showed hearing deterioration during therapy; however, only two patients showed objective radiological response. Seven of eight patients had tumor progression or worsening hearing loss upon cessation of treatment. Bevacizumab was well tolerated with no patients discontinuing therapy. Bevacizumab appears to postpone hearing loss in childhood NF2-associated vestibular schwannomas, but responses are not durable, suggesting that either longer maintenance therapy or new strategies are required.
650    _2
$a mladiství $7 D000293
650    _2
$a bevacizumab $x aplikace a dávkování $7 D000068258
650    _2
$a dítě $7 D002648
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a neurofibromin 2 $x metabolismus $7 D025581
650    _2
$a vestibulární schwannom $x farmakoterapie $x metabolismus $x patologie $x patofyziologie $7 D009464
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Michaeli, Orli $u Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada. Division of Haematology/Oncology, Schneider Medical Center of Israel, Petah Tikva, Israel.
700    1_
$a Salvador, Hector $u Pediatric Oncology Department, Neurocutaneous Disorders and Cancer Predisposition Unit, Sant Joan de Deu, Barcelona, Spain.
700    1_
$a Alderete, Daniel $u Service of Hematology/Oncology, Hospital JP Garrahan, Buenos Aires, Argentina.
700    1_
$a Ponce, Nicolas Fernandez $u Service of Hematology/Oncology, Hospital JP Garrahan, Buenos Aires, Argentina.
700    1_
$a Zapotocky, Michal $u Department of Paediatric Haematology and Oncology, Second Medical School, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Hansford, Jordan R $u Children's Cancer Centre, Royal Children's Hospital, Melbourne, Australia. Division of Cancer, Murdoch Children's Research Institute, Melbourne, Australia.
700    1_
$a Malalasekera, Vajiranee S $u Children's Cancer Centre, Royal Children's Hospital, Melbourne, Australia.
700    1_
$a Toledano, Helen $u Division of Haematology/Oncology, Schneider Medical Center of Israel, Petah Tikva, Israel. Sackler Medical School, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Maguire, Bryan $u Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Bouffet, Eric $u Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Ramaswamy, Vijay $u Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada. Department of Medical Biophysics and Paediatrics, University of Toronto, Toronto, Ontario, Canada.
700    1_
$a Baroni, Lorena V $u Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada. Service of Hematology/Oncology, Hospital JP Garrahan, Buenos Aires, Argentina.
773    0_
$w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 67, č. 5 (2020), s. e28228
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32124552 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155028 $b ABA008
999    __
$a ok $b bmc $g 1599209 $s 1115750
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 67 $c 5 $d e28228 $e 20200302 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
GRA    __
$p CIHR $2 Canada
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options